Skip to main content
Bafna Pharmaceuticals Limited logo

Bafna Pharmaceuticals Limited — Investor Relations & Filings

Ticker · BAFNAPH ISIN · INE878I01022 LEI · 984500D03E2C7Y5EE587 BSE.NS Manufacturing
Open in API
Filings indexed 247 across all filing types
Latest filing 2024-09-26 Regulatory Filings
Country IN India
Listing BSE.NS BAFNAPH

About Bafna Pharmaceuticals Limited

http://bafnapharma.com/

Bafna Pharmaceuticals Limited specializes in the development, manufacture, and marketing of a diverse range of pharmaceutical formulations. The company operates manufacturing facilities certified by WHO-GMP standards, ensuring high-quality production of finished dosage forms including tablets, capsules, syrups, and suspensions. Its therapeutic portfolio spans multiple categories such as anti-infectives, analgesics, cardiovascular, gastrointestinal, and vitamins. The organization serves both domestic and international markets, with a significant presence in emerging regions across Africa, Southeast Asia, and the CIS. In addition to its proprietary product line, the company provides comprehensive contract manufacturing and formulation development services, leveraging its technical expertise and regulatory compliance to meet global healthcare requirements.

Recent filings

Filing Released Lang Actions
Shareholders meeting
Regulatory Filings
2024-09-26 English
Change in Director(s)
Board/Management Information Classification · 100% confidence The document is a formal disclosure addressed to stock exchanges pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015. It announces the re-appointment of Ms. S Hemalatha as Whole Time Director of the company, approved at the 29th Annual General Meeting held on September 25, 2024. The content focuses on management changes, including terms of appointment and brief profile of the director. There are no financial statements or detailed financial performance data. The document is not an annual report, earnings release, or any financial report but rather an announcement of a board/management change. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is 4256 characters, which is sufficient for a detailed announcement but not a full report.
2024-09-25 English
Shareholders meeting
AGM Information Classification · 100% confidence The document is a detailed summary of the proceedings of the 29th Annual General Meeting (AGM) of Bafna Pharmaceuticals Limited held on September 25, 2024. It includes information about the meeting's conduct, attendance, agenda items, voting procedures, and resolutions passed. The document explicitly states it is a "Summary of Proceedings of 29th Annual General Meeting" and is submitted pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015. It does not contain the full annual report or financial statements but rather a summary of the AGM event itself. Therefore, this document fits the category of AGM Information (AGM-R). The document length (7937 characters) supports it being a detailed summary rather than a brief announcement or a full annual report.
2024-09-25 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short announcement dated September 09, 2024, addressed to stock exchanges (BSE and NSE) regarding an award received by Bafna Pharmaceuticals Limited from the Pharmaceuticals Export Promotion Council of India. It is a disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015, which pertains to material event disclosures. The content is about an award recognition and does not contain financial data, management discussion, or any report. It is not a report itself but a regulatory announcement of a material event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-09-09 English
Copy of Newspaper Publication
Report Publication Announcement Classification · 95% confidence The document is a letter addressed to stock exchanges confirming the dispatch of the Notice of the 29th Annual General Meeting (AGM) and the Annual Report for the financial year 2023-2024. It mentions the publication of newspaper notices confirming this dispatch. The document itself does not contain the Annual Report or the Notice but is an announcement about their dispatch and publication. The document length is short (1866 characters), and it explicitly states that the Notice and Annual Report have been dispatched and published elsewhere. According to the 'Menu vs Meal' rule, this is an announcement about the report, not the report itself. Therefore, the correct classification is Report Publication Announcement (RPA).
2024-09-03 English
Shareholders meeting
Regulatory Filings
2024-09-02 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.